EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

In Silico Prediction of EZHIP Post-Translational Modification Sites and Small-Molecule High-Throughput Screening for Quantitative EZHIP Modulation

Jimin Moon iD, Jiwon Hwang iD, Chan Chung iD

Brain Tumor Research and Treatment · 2026 · 14 (2) · 91

DOI: 10.14791/btrt.2025.0047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Tumor Research and Treatment, 2026. Verfasst von Jimin Moon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of New Biology, DGIST, Daegu, Korea. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korean Society for Neuro-Oncology, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Posterior fossa group A (PFA) ependymoma is a lethal pediatric brain tumor driven predominantly by epigenetic dysregulation. Enhancer of Zeste Homologs Inhibitory Protein (EZHIP) is a defining oncogenic factor in PFA ependymoma that inhibits PRC2 activity, inducing a global loss of H3K27me3 and sustaining aberrant developmental transcriptional programs. Although the metabolic modulator, metformin, reduces EZHIP protein levels, the mechanisms governing EZHIP regulation remain undefined. METHODS: post-translational modification prediction was performed using PhosphoSitePlus and NetPhos 3.1 to identify candidate regulatory residues and upstream kinases. A focused panel of pathway targeting compounds was evaluated using fluorescence-based high-throughput screening, followed by secondary validation including cell counting, LC₅₀ (half-maximal lethal concentration) analysis, and Western blotting. RESULTS: Computational analyses identified multiple high-confidence serine phosphorylation sites on EZHIP and implicated AMPK, MAPK, PKC, AKT, and CK2 signaling pathways. High-throughput screening revealed that activation of the AMPK axis robustly suppressed EZHIP protein levels. Secondary validation demonstrated that biguanides activating AMPK reduced EZHIP abundance independently of cytotoxicity and restored global H3K27me3 levels. In contrast, PKC activation increased EZHIP protein abundance. CONCLUSION: Our study identifies EZHIP as a dynamically regulated oncoprotein controlled by post-translational signaling pathways. AMPK and PKC exert opposing effects on EZHIP stability, defining actionable regulatory mechanisms for therapeutic targeting in EZHIP-driven cancers.

Schlagwörter

Stichwörter der Autor:innen

Drug developmentEZHIP proteinEpendymomaHigh-throughput screening assayPost-translational modification

Autor:innen und Institutionen

  • Department of New Biology, DGIST, Daegu, Korea.
  • New Biology Research Center (NBRC), DGIST, Daegu, Korea. chungc@dgist.ac.kr.

ORCID-Profile: Jimin Moon, Jiwon Hwang, Chan Chung

Förderung

  • Korean Society for Neuro-Oncology
  • National Research Foundation of Korea

Zitieren

APA

Moon, J., Hwang, J., & Chung, C. (2026). In Silico Prediction of EZHIP Post-Translational Modification Sites and Small-Molecule High-Throughput Screening for Quantitative EZHIP Modulation. Brain Tumor Research and Treatment, 14(2), 91. https://doi.org/10.14791/btrt.2025.0047

Vancouver

Moon J, Hwang J, Chung C. In Silico Prediction of EZHIP Post-Translational Modification Sites and Small-Molecule High-Throughput Screening for Quantitative EZHIP Modulation. Brain Tumor Research and Treatment. 2026;14(2):91. doi:10.14791/btrt.2025.0047

BibTeX
@article{Moon2026,
  author = {Moon, Jimin and Hwang, Jiwon and Chung, Chan},
  title = {In Silico Prediction of EZHIP Post-Translational Modification Sites and Small-Molecule High-Throughput Screening for Quantitative EZHIP Modulation},
  journal = {Brain Tumor Research and Treatment},
  year = {2026},
  volume = {14},
  number = {2},
  pages = {91},
  doi = {10.14791/btrt.2025.0047}
}
Kostenlos starten →